...
首页> 外文期刊>Annals of Cancer Research and Therapy >Meta-analysis of Patient-level Data on Therapeutic Effects of TJ-14 (Hangeshashinto) for Gastroenterological Cancer Chemotherapy-induced Severe Oral Mucositis with the HANGESHA-G and HANGESHA-Cs : protocol paper
【24h】

Meta-analysis of Patient-level Data on Therapeutic Effects of TJ-14 (Hangeshashinto) for Gastroenterological Cancer Chemotherapy-induced Severe Oral Mucositis with the HANGESHA-G and HANGESHA-Cs : protocol paper

机译:关于HANGESHA-G和HANGESHA-Cs对TJ-14(Hangeshashinto)治疗胃肠道癌化学疗法诱发的严重口腔粘膜炎的疗效的患者水平数据的荟萃分析:方案文件

获取原文
           

摘要

This meta-analysis will be performed to evaluate the efficacy of Hangeshashinto (TJ-14) in patients with chemotherapy-induced oral mucositis (COM) for gastroenterological cancer. Individual patient–level data from two prospective, double-blind, placebo-controlled randomized trials employing the same regimens using TJ-14 will be collected for this study. Cumulative data from 181 patients will help conclude whether TJ-14 is effective to COM for gastroenterological cancer or not. We will select the patients with severe (CTCAE grade ≥2) COM who did not reduce the dose of chemotherapy to evaluate the effect of TJ-14 precisely. The primary endpoint of this study is time to remission of severe (CTCAE grade ≥2) COM to grade ≤1 in the protocol treatment course, and the secondary end points are the incidence of grade ≥2 COM, and predictive factors of time to remission and of incidence of grade ≥2 COM.
机译:进行这项荟萃分析,以评估Hangeshashinto(TJ-14)在化疗引起的口腔粘膜炎(COM)消化道癌患者中的疗效。本研究将收集来自两项采用相同方案,使用TJ-14的前瞻性,双盲,安慰剂对照随机试验的患者水平数据。来自181名患者的累积数据将有助于得出结论,TJ-14对COM胃肠道癌是否有效。我们将选择未降低化疗剂量的严重(CTCAE≥2级)COM患者,以准确评估TJ-14的疗效。这项研究的主要终点是在协议治疗过程中重度(CTCAE≥2级)COM缓解至≤1级的时间,次要终点是≥2 COM的发生率以及缓解时间的预测因素且≥2 COM的发生率。

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号